[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertension-resistant-to-conventional-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertension-resistant-to-conventional-therapy":56},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,72,93,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100640561","expand-management-of-blood-pressure-with-renal-denervation-in-patients-undergoing-staged-pci-for-advanced-coronary-artery-disease-100640561",false,"NCT07602790","Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery diseasE","Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery Disease","EMBRACE","Inclusion Criteria:\n\n* Subject with multi-vessel disease\n* Having successful index PCI and planned staged procedure within 1-6 weeks to complete revascularization\n* Subjects ≥21 years of age\n* Office systolic blood pressure at index procedure and\u002For staged procedure (systolic blood pressure \\>140 mmHg) while taking 2 or more antihypertensive drugs\n* Subject agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study prior to staged procedure\n\nExclusion Criteria:\n\n* \\- Contraindication for RDN outlined by IFU\n* Acute MI at time of the staged PCI procedure (AMI at time of the index PCI is allowed)\n* Subject has undergone prior renal denervation.\n* Subject has renal artery anatomy that is ineligible for RDN treatment per Symplicity Spyral™ IFU\n* Known secondary cause (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, or other identifiable etiologies).\n* Severe renal failure (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²)\n* Known LVEF \\\u003C30%\n* Known history of polycystic kidney disease, unilateral kidney, or undergone renal transplant\n* Mechanical circulatory support during PCI\n* Subject is under judicial protection, tutorship or curatorship\n* Failure of index procedure\n* Acute MI, severe renal failure, need for mechanical circulatory support, or legal incapacity between the index and staged procedures resulting in loss of eligibility.","ALL","21 Years",{"count":20,"type":21},1000,"ESTIMATED","INTERVENTIONAL",[24],"NA","EMBRACE is a randomized, controlled, multicenter clinical study evaluating the effect of renal denervation on clinical adverse events in hypertensive patients undergoing staged percutaneous coronary intervention (PCI) for multivessel coronary artery disease.",[27,28],"Multivessel Coronary Artery Disease","Hypertension Resistant to Conventional Therapy","NOT_YET_RECRUITING","2026-05-18",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":21},"2026-11",{"date":37,"type":21},"2033-11",{"name":39,"class":40},"Ceric Sàrl","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100535020","phase-4-antihypertensive-mechanisms-of-minocycline-in-resistant-hypertension-100535020","NCT06246396","Antihypertensive Mechanisms of Minocycline in Resistant Hypertension","Antihypertensive Mechanisms of Minocycline in Resistant Hypertension: Role of the Gut Microbiota-brain-immune Axis","Inclusion Criteria:\n\n* Age ≥18 years\n* Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic.\n* The participant agrees to have all study procedures performed\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindication to minocycline or other tetracyclines\n* Recent (≤3 months prior), ongoing, or expected use of oral antibiotics\n* Estimated glomerular filtration rate (eGFR) of \\\u003C45mL\u002Fmin\u002F1.73m2, using the MDRD equation\n* Known secondary hypertension\n* History of hypertensive crisis, defined as any in-patient hospitalizations for hypertensive crisis\u002Femergency within the past year\n* History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of \\>20 mm Hg or DBP of \\>10 mm Hg within 3 minutes of standing) in the past year\n* History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months\n* Evidence of alcoholism or drug abuse\n* Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS)\n* Current pregnancy or anticipated pregnancy during the study.","18 Years","100 Years",{"count":51,"type":21},120,[53],"PHASE4","The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are:\n\n* To what extent does minocycline lower blood pressure?\n* Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these?\n\nParticipants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.",[56],"Hypertension, Resistant to Conventional Therapy",[58,59],"minocycline","blood pressure","RECRUITING","2026-03-05",{"date":63,"type":33},"2026-03-06",{"date":65,"type":33},"2025-01-08",{"date":67,"type":21},"2028-07",{"name":69,"class":70},"University of Florida","OTHER",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100555963","baroloop-multicenter-trial-baroloop-mct-100555963","NCT06518915","Baroloop Multicenter Trial (Baroloop MCT)","Baroloop MCT - A Multicenter Trial of Safety and Performance of Baroloop","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Persistent office systolic blood pressure (SBP) ≥ 140 mm Hg and diastolic blood pressure (DBP) \\> 90 mm Hg on antihypertensive medicines on two visits separated by a minimum of four weeks.\n3. Mean 24-hour systolic ABPM ≥ 130 mm Hg and mean 24 hour diastolic ABPM ≥ 80 mm Hg conducted after direct observed therapy to confirm that antihypertensive medicines were taken as prescribed during the ABPM measurement.\n4. Stable drug regimen of 3 antihypertensive medicines consisting of a reninangiotensin blocker (ACE) or Angiotensin II Receptor Blocker (ARBs), a calcium channel blocker (CCB), and a diuretic for 4 weeks at treatment.\n5. Willingness and ability to comply with follow-up requirements.\n6. Signed informed consent.\n\nExclusion Criteria:\n\n1. Any patient in whom access to the vagal nerve is limited by the size of the vagus (a size not compatible with the baroloop cuff).\n2. Any patient with a history of injury to the vagus nerve or its branches (e.g., the recurrent laryngeal nerve).\n3. Secondary causes of hypertension.\n4. Calculated eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2.\n5. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1c \\> 10%).\n6. Requirement for chronic oxygen therapy or mechanical ventilation.\n7. Untreated (no CPAP therapy) sleep apnea (AHI \\> 15)\n8. Morbid obesity, defined as Body Mass Index \\>40 kg\u002Fm2 or arm circumference 46 cm.\n9. Pacemaker and\u002For implantable defibrillators.\n10. History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening.\n11. Symptomatic carotid artery disease or \\> 70% occlusion of either carotid artery; any carotid malformation or lesion, a carotid bruit or other abnormal carotid sound.\n12. Prior surgery, radiation therapy or scarring in the neck in the region of the carotid artery (e.g., patients with a tracheostomy, extensive thymectomy or thyroid surgery).\n13. Limited mobility of the neck secondary to vertebral disease or prior vertebral surgery, including patients who wear a cervical support.\n14. History of heart failure (NYHA class III-IV).\n15. Cardiac arrythmias (atrial fibrillation, atrial flutter, etc.) that require anticoagulation if the condition interferes with a consistent measurement of blood pressure.\n16. Unexplained syncope in the last 6 months.\n17. History of bleeding disorders, thrombocytopenia, hemophilia, or significant anemia (hemoglobin (Hgb) \\\u003C 10 g\u002Fdl).\n18. Current anticoagulation therapy (excluding antiplatelet therapy with aspirin as a sole therapy).\n19. History of unresolved drug or alcohol use.\n20. Active treatment of a psychiatric ailment.\n21. Life expectancy of less than 12 months due to other disease.\n22. Subject has a condition that, in the opinion of the investigator, precludes participation, including willingness to comply, with all follow-up procedures.\n23. Participation in another clinical study for which follow-up is currently on-going.\n24. Women who are pregnant\n25. Resting heart rateof \\\u003C 45 beats\u002Fmin s, confirmed at both baseline visits.\n26. Baroreflex failure or autonomic neuropathy\n27. Symptomatic, uncontrolled bradyarrhythmias\n28. Atrioventricular block of any grade\n29. Presence of a vagus stimulator\n30. Patients who are likely to require magnetic resonance imaging (MRI) of the cervical area\n31. Occupational exposure to high levels of non-ionizing radiation that may interfere with therapy\n32. Patients with a limited ability to read, understand and execute adjustment procedures (for example, persons suffering from dementia).\n33. Likely exposure to diathermy.",{"count":51,"type":21},[24],"The goal of this clinical trial is to learn weather the baroloop system is safe and works to treat hypertension in adults that do not respond sufficiently to medication. The main questions it aims to answer are:\n\n* Is the baroloop device associated with any major medical problems including death?\n* Does the baroloop lower the blood pressure of study participants?\n\nParticipants will be implanted with the baroloop device. Afterwards they will visit the clinic after 14 days, 3 months, 6 months, 12 months, 18 months, and 24 months for adjustment of the device settings and\u002For other study related assessments. Participants will also be asked to answer questions regarding their quality of life.",[56],"2025-04-14",{"date":85,"type":33},"2025-04-17",{"date":87,"type":33},"2024-05-22",{"date":89,"type":21},"2031-12",{"name":91,"class":40},"neuroloop GmbH",4,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":17,"minAge":48,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":115,"locationsCount":5},"100213607","physical-activity-program-for-reducing-blood-pressure-in-sleep-apnea-patients-with-resistant-hypertension-100213607","NCT02057783","Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension","Comparison of Standard Treatment by Continuous Positive Airway Pressure (CPAP) and CPAP Combined to a Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension: RAP Randomized Controlled Trial","RAP","Inclusion Criteria:\n\n* Patient with an obstructive sleep apnea (apnea-hypopnea index \\> or equal to 15)\n* Patient with resistant hypertension uncontrolled by 3 or more antihypertensive agents\n* Ambulatory patient\n\nExclusion Criteria:\n\n* Acute hepatic failure, biliary cirrhosis, cholestasis\n* Acute hypertension (SBP\\>= 180 mmHg and\u002For DBP \\>= 110 mmHg)\n* Contraindication to CPAP treatment",true,"80 Years",{"count":104,"type":21},100,[24],"Investigators hypothesize that CPAP treatment for suppressing OSAS in combination with a physical activity program will optimize 24-hour blood pressure control in patients with OSA-related resistant hypertension.",[56,108],"Sleep Apnea","2025-02-18",{"date":111,"type":33},"2025-02-20",{"date":113,"type":33},"2015-03-26",{"date":109,"type":21},{"name":116,"class":70},"AGIR à Dom",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":71},"100565778","a-preventive-multidisciplinary-primary-care-intervention-organized-around-a-therapeutic-garden-acceptability-to-patients-suffering-from-cardio-neurovascular-pathology-and-to-those-involved-in-the-action-100565778","NCT06646601","A Preventive, Multidisciplinary Primary Care Intervention Organized Around a Therapeutic Garden: Acceptability to Patients Suffering from Cardio-neurovascular Pathology and to Those Involved in the Action.","ArTERRE","Inclusion Criteria:\n\n* age \\> 18 years old;\n* living in the vicinity (+-20 km) of Gap, Laragne-Montéglin, Veynes and Clermont-Ferrand;\n* having been invited to take part in the intervention by the caregivers of the medical structures\n* suffering from an ALD based on CNAM medical criteria (stroke, AOMI, rhythm disorders, valvular heart disease, congenital heart disease, stage I and II heart failure), severe hypertension, chronic coronary disease)\n\nExclusion Criteria:\n\n* heart failure based on CNAM medical criteria (ALD n°5) stage III and IV according to NYHA classification ;\n* with a contraindication to physical activity ;\n* living in an institution;\n* unable to walk more than 100 m independently;\n* Alzheimer's disease or other dementias based on CNAM medical criteria ;\n* with an unlabelled cognitive impairment limiting comprehension.",{"count":125,"type":21},157,[24],"A preventive, multidisciplinary primary care intervention organized around a therapeutic garden: Acceptability to patients suffering from cardio-neurovascular pathology and to those involved in the action.",[129,130,131,132,133,134,28],"Vascular Disease","Cardiovascular","Atrial Fibrillation (AF)","Heart Failure NYHA Class II","Cardiomyopathies","Stroke, Ischemic","2024-10-15",{"date":137,"type":33},"2024-10-17",{"date":139,"type":33},"2024-04-09",{"date":141,"type":21},"2026-10",{"name":143,"class":70},"Assistance Publique Hopitaux De Marseille"]